We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.

Stay informed

Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.



Event When
Citi BioPharma Conference

September 7-8, 2022

Morgan Stanley Global Healthcare Conference

September 12-14, 2022

Bank of America Global Healthcare Conference

September 14-16, 2022

Baader Investment Conference 

September 19-23, 2022

Nine-months 2022 Financial Results reporting*

October 25, 2022

Credit Suisse Healthcare Conference 

November 7-10, 2022

Full-Year 2022 Financial Results reporting*

February 7, 2023

First Quarter 2023 Financial Results reporting*

April 25, 2023

*We will be in a silent period for 10 days ahead of the financial reporting.

Financial information

Financial information

The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.

Our strategy

Our strategy

Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.

Development pipeline

Development pipeline

Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.

Corporate reports

Corporate reports

The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.

Stock information

Stock information

The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.



Andrew C. Weiss

Senior Vice President, Head of Investor Relations and Corporate Communications